McClellan Leads the Way to New Postmarketing World

Midway through the 2007 Congressional debate over new drug safety controls, Mark McClellan, MD, is emerging as a figure with the credentials, credibility and fund-raising capability to make the establishment of a public-private partnership for post-marketing surveillance a reality. Big Pharma better hope that McClellan is ultimately successful. If ever there was a time when a new, authoritative voice was needed to provide clarity to postmarketing safety issues, it is now.

Midway through the Congressional debate over new drug safety controls, Mark McClellan, MD, is emerging as a figure with the credentials, credibility and fund-raising capability to make the establishment of a public-private partnership for post-marketing surveillance a reality.

Big Pharma better hope that McClellan is ultimately successful. If ever there was a time when a new, authoritative voice...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet